1. Home
  2. MURA vs DYAI Comparison

MURA vs DYAI Comparison

Compare MURA & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.03

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Logo Dyadic International Inc.

DYAI

Dyadic International Inc.

HOLD

Current Price

$0.93

Market Cap

30.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MURA
DYAI
Founded
2013
1979
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
30.2M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
MURA
DYAI
Price
$2.03
$0.93
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$6.00
$3.00
AVG Volume (30 Days)
224.8K
527.8K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,342,195.00
Revenue This Year
N/A
$12.52
Revenue Next Year
N/A
$92.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$0.71
52 Week High
$4.74
$2.20

Technical Indicators

Market Signals
Indicator
MURA
DYAI
Relative Strength Index (RSI) 40.39 43.36
Support Level $2.06 $0.89
Resistance Level $2.10 $1.04
Average True Range (ATR) 0.01 0.10
MACD -0.01 0.00
Stochastic Oscillator 25.00 21.01

Price Performance

Historical Comparison
MURA
DYAI

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About DYAI Dyadic International Inc.

Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Share on Social Networks: